---
title: "HSBC Research's Investment Ratings and Target Prices for Pharmaceutical and Biotechnology Stocks (Table)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/259748360.md"
description: "HSBC Research has released its latest investment ratings and target prices for pharmaceutical and biotechnology stocks. The main stocks and their ratings include: BeiGene (Buy, target price USD 375), Innovent Biologics (Buy, target price HKD 115), Kelun-Biotech (Buy, target price HKD 549), China National Pharmaceutical Group (Buy, target price HKD 9.6), CSPC Pharma (Buy, target price HKD 10.5), Hengrui Pharma (Buy, target price RMB 79), Fosun Pharma (Hold, target price HKD 26.5), LIVZON PHARMA (Hold, target price HKD 37.23), HANSOH PHARMA (Buy, target price HKD 47)"
datetime: "2025-10-02T07:07:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/259748360.md)
  - [en](https://longbridge.com/en/news/259748360.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/259748360.md)
generator: "portal-rs"
---

# HSBC Research's Investment Ratings and Target Prices for Pharmaceutical and Biotechnology Stocks (Table)

HSBC Research published a research report, listing the latest investment ratings and target prices for pharmaceutical and biotechnology stocks as follows:

Stock | Investment Rating | Target Price

BeiGene (ONC.US) | Buy | USD 323 -> USD 375

Innovent Biologics (01801.HK) | Buy | HKD 110 -> HKD 115

Kintor Pharmaceutical (06990.HK) | Buy | HKD 354 -> HKD 549

China National Pharmaceutical Group (01177.HK) | Buy | HKD 8.49 -> HKD 9.6

CSPC Pharma (01093.HK) | Buy | HKD 10.7 -> HKD 10.5

Hengrui Pharma (600276.SH) | Buy | RMB 73 -> RMB 79

Fosun Pharma (02196.HK) | Hold | HKD 17.2 -> HKD 26.5

LIVZON PHARMA (01513.HK) | Hold | HKD 37.54 -> HKD 37.23

HANSOH PHARMA (03692.HK) | Buy | HKD 47

### Related Stocks

- [000513.CN](https://longbridge.com/en/quote/000513.CN.md)
- [01513.HK](https://longbridge.com/en/quote/01513.HK.md)
- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)
- [03692.HK](https://longbridge.com/en/quote/03692.HK.md)
- [600276.CN](https://longbridge.com/en/quote/600276.CN.md)

## Related News & Research

- [Livzon Pharma buys 3.5% Xinbeijiang Pharma stake for RMB 106.7 million](https://longbridge.com/en/news/296601614.md)
- [CSPC PHARMA  Shares Rise 15% as Phase Ib/II Clinical Trial of SYS 6090 Injection for Hepatocellular Carcinoma Launches at First Center in China](https://longbridge.com/en/news/296423040.md)
- [CSPC PHARMA  1H26 Net Profit Surges Nearly 1.4x, Interim DPS Up 28.6% to HKD0.18](https://longbridge.com/en/news/296435690.md)
- [CSPC Pharma FY26 H1 profit attributable to shareholders more than doubled to RMB 6.09 billion; revenue rises 40.1% to RMB 18.59 billion](https://longbridge.com/en/news/296433558.md)
- [M Stanley Raises CSPC PHARMA  TP to HKD12, Rating Overweight](https://longbridge.com/en/news/296557755.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**